Search Results for “ oncology” – Page 5 – media

Illumina and KingMed to develop oncology diagnostics in China

US-based gene sequencing firm Illumina has signed an agreement with Guangzhou KingMed Diagnostics Group to co-develop new oncology and hereditary disease testing applications in China.
- Source: Verdict Medical Devices
- 640
- January 9, 2018
cancer CFDA Company Insight digital health
More than 2,000 immune-oncology drugs now in development

A new report has found that there are more than 2,000 immunotherapy drugs now in development for cancer, with 940 of these in clinical stage development and 1,064 at the preclinical stage.
- Source: pharmatimes
- 477
- December 11, 2017
immuno-oncology immunotherapy drugs immuotherapy agents
Loxo Oncology Lands $1.55B Cancer Tie-Up With Bayer

Loxo Oncology struck a deal with Germany-based Bayer AG to develop and commercialize two cancer therapies in a deal that could be worth up to $1.55 billion for the Connecticut-based company.
- Source: Biospace
- 832
- November 16, 2017
cancer larotrectinib Market Views therapy TRK
AbbVie and Harpoon Therapeutics Announce Immuno-Oncology Research Collaboration

"This collaboration is the first for Harpoon and highlights the high level of industry interest in best-in-class platform technologies. We are excited about partnering with AbbVie to help generate novel T-cell engagers for the treatment of cancer based on the combination of T-cell receptors with TriTACs," said Jerry McMahon, Ph.D., chief executive officer, Harpoon Therapeutics.
- Source: finance.yahoo
- 684
- October 23, 2017
AbbVie Market Views T-cell recruiting biologic
Takeda partners to develop novel oncology therapies

Collaboration on an oncology drug discovery program was inked between Takeda Pharmaceutical, through its subsidiary Millennium Pharmaceuticals, and Molecular Templates.
- Source: drugdeliverybusiness
- 846
- August 28, 2017
Company Insight Market Views oncology therapy
Cornerstone Pharmaceuticals has reached a strategic cooperation on anti-PD-L1 monoclonal antibodies in the Middle East and Africa regions

Editor of WuXi AppTec Content Team On November 21st, Cornerstone Pharmaceuticals announced a commercial strategic partnership with Pharmalank Store. Pharmalank is a well-known pharmaceutical company headquartered in the United Arab Emirates. According to the licensing and commercialization agreement, Pharmalank will acquire the commercialization rights of Shuglimab in the Middle East and North Africa region, including Saudi Arabia, United Arab Emirates, Kuwait, Qatar, Oman, Bahrain, Algeria, Tunisia, Egypt, Morocco, Libya, and South Africa. According to the agreement, Cornerstone Pharmaceuticals will receive the down payment and subsequent registration milestone payments from Pharmarlink, as well as royalties for the net sales of Shuglimab, while Pharmarlink will be responsible for Shuglimab registration and commercialization related activities in the aforementioned regions. Cornerstone Pharmaceuticals will be responsible for the supply of Shuglimab products. According to a press release from Cornerstone Pharmaceuticals, following the strategic partnership reached with Ewopharma in Central/Eastern Europe and Switzerland in the first ...
- Source: drugdu
- 31
- November 22, 2024
China Biopharmaceuticals announces signing equity investment and strategic cooperation agreement with Lixin Pharmaceutical

China Biopharmaceutical invested in New Pharmaceuticals with self raised funds, and reached strategic cooperation on LM-108 and many potential innovative bispecific antibodies or antibody conjugated drugs (ADC) in Chinese Mainland. According to the announcement, this agreement includes equity investment and strategic cooperation. In terms of equity investment, Lixin Pharmaceutical announced on October 18, 2024, the completion of a RMB 300 million C1 round of financing, raising funds to accelerate the development of clinical pipeline drugs and the construction of innovation platforms. According to the capital increase subscription agreement, China Biopharmaceutical, as the lead investor in this round of financing, paid RMB 142 million to Lixin Pharmaceutical and acquired 4.91% equity of Lixin Pharmaceutical after this transaction. In terms of strategic cooperation: China Biopharmaceutical and Lixin Pharmaceutical reached a strategic cooperation agreement on LM-108 in Chinese Mainland. In addition, Chinese biopharmaceuticals have the right to choose multiple bispecific antibodies or ADC ...
- Source: drugdu
- 28
- November 22, 2024
Regeneron’s midlife crisis

Regeneron is a role model for the biotech community. No biotech company wants to be Regeneron. “Becoming China’s Regeneron” is the slogan of many domestic biotechs. However, such a Regeneron cannot escape its midlife crisis. The attack of opponents, the victory of Eylea generic drugs, and the successive blows of dual-antibodies have put Regeneron in an extremely delicate stage. On the one hand, with two blockbuster drugs, Regeneron has completed the transformation from biotech to big pharma. In the first half of the year, its stock price continued to rise, successfully breaking through the $100 billion threshold, and its market value reached $133.2 billion. On the other hand, although the market believes in Regeneron’s R&D and platform technology capabilities, how can a new billion-dollar blockbuster drug be so easy? And Regeneron’s highly anticipated oncology business is not as glamorous as autoimmunity and ophthalmology, and its progress is also lackluster. So ...
- Source: drugdu
- 29
- November 22, 2024
Over 5.7 billion! China’s dual antibody ADC goes global+1

On November 18th, VelaVigo Cayman Limited announced a global strategic partnership agreement with Avenzo Therapeutics, Inc. (Avenzo). According to the agreement, Orange Sail Pharmaceuticals will grant Avenzo the development, production, and commercialization of Nectin4/TROP2 bispecific antibody conjugates worldwide (excluding Greater China), while retaining relevant rights in Greater China. Both parties will jointly promote the development and clinical application of the project on a global scale. The project plans to submit an IND to the US Food and Drug Administration (FDA) and the National Medical Products Administration (NMPA) of China by 2025. According to the terms of the agreement, Orange Sail Pharmaceuticals will receive a down payment of up to $50 million and recent milestone payments. After achieving key milestones in development, regulatory approval, and sales, the company is expected to receive up to $750 million in follow-up milestone payments and tiered royalty payments based on sales in the Avenzo region. ...
- Source: drugdu
- 43
- November 21, 2024
Global product revenue exceeds 7 billion yuan! BeiGene’s third quarter report is released

On the evening of November 12, BeiGene released its 2024 third quarter US stock performance report and A-share main financial data announcement. In the third quarter, BeiGene continued its strong growth momentum, achieving revenue of 7.139 billion yuan, a year-on-year increase of 26.9%. Global product revenue reached 7.079 billion yuan, a year-on-year increase of 65.1%. In the first three quarters of 2024, BeiGene’s total operating revenue reached 19.136 billion yuan, a year-on-year increase of 48.6%. Products continued to increase in volume at a high speed, with product revenue of 18.986 billion yuan in the first three quarters, a year-on-year increase of 72.9%. Whether it is total revenue or product revenue, the first three quarters have exceeded last year’s full-year revenue of 17.423 billion yuan, and the performance is very eye-catching. The US stock financial report shows that BeiGene’s financial situation continues to improve, with total revenue of US$1.002 billion this ...
- Source: drugdu
- 36
- November 18, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.